Annotation of SLCO1B1*1, SLCO1B1*15
SLCO1B1 *15 is associated with increased exposure to pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1.
From Publication
Gene
Haplotype
Phenotype Category
Association Significance
PharmGKB ID
Score More info on scoring
Evidence for Clinical Annotations
This annotation has been used as evidence for the following clinical annotations.
Study Parameters
1.
Study type
Study size
Association p-value
Biogeographical group More info on groups
Population description
Study Cohort: P-value given for differences in Cmax between genotype groups.
2.
Study type
Study size
Association p-value
Biogeographical group More info on groups
Population description
Study Cohort: P-value given for differences in AUClast between genotype groups.
3.
Study type
Study size
Association p-value
Biogeographical group More info on groups
Population description
Study Cohort: P-value given for differences in AUCinf between genotype groups.
4.
Study type
Study size
Association p-value
Biogeographical group More info on groups
Population description
Study Cohort: P-value given for differences in Cl/F between genotype groups.
5.
Study type
Study size
Association p-value
Biogeographical group More info on groups
Population description
Study Cohort: P-value given for differences in Tmax between genotype groups.
6.
Study type
Study size
Association p-value
Biogeographical group More info on groups
Population description
Study Cohort: P-value given for differences in half-life between genotype groups.
Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.
History
No history available.